Login / Signup

Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.

Jaume MoraGodfrey Chi Fung ChanDaniel A MorgensternKarsten NysomMelissa K BearKaren TornøeBrian H Kushner
Published in: Cancer reports (Hoboken, N.J.) (2022)
This article highlights the protocol-based recommendations for the management of acute AEs associated with outpatient naxitamab treatment in Trial 201. The authors recommend close monitoring and timely implementation of measures to ensure that patients can remain on treatment and obtain maximum clinical benefit from naxitamab therapy.
Keyphrases